CA
NZ
UK
AU
IND
US
Nasdaq said after Thursday's close that Moderna will replace Warner Bros. Discovery in the Nasdaq-100 before the open on October 9. Moderna has more than sextupled this year, making it the S&P 500's second-best performer. Retail traders on social platforms used the news to …
Eli Lilly and Company (NYSE: LLY) is slipping modestly on Thursday as sellers keep control of a stock that has spent six weeks failing to hold above its moving averages. As of this chart snapshot (about 30 minutes before the close), shares are trading …
Merck & Co., Inc. (NYSE: MRK) is under pressure on Thursday, extending a pullback from its late-August high. As of this chart snapshot (about 30 minutes before the close), shares are trading at $143.49, down $1.82 (-1.26%). The stock opened at $144.71, traded to …
McKesson Corporation (NYSE: MCK) is having a strong session after weeks of drifting lower. As of this chart snapshot (about 30 minutes before the close), shares are trading at $898.97, up $45.16 (+5.29%). The stock gapped up from Wednesday's close near $853.81 to open …
Alnylam Pharmaceuticals (NASDAQ:ALNY) is falling in Thursday's session as investors keep weighing the outlook for its ATTR-CMFranchisefollowing a failed trial from AstraZeneca (NYSE:AZN) and a partner in the same disease area. The Cambridge, Massachusetts-based company pioneered RNA interference therapeutics, and its approved therapies include …
agilon health (NYSE:AGL) is rising in Thursday's session as investors digest a run of accountable care organizationPartnershipexpansions, the latest announced on September 30. The Westerville, Ohio-based company partners with community-based primary care physician groups to deliver value-based care to senior patients.
Amgen (NASDAQ:AMGN) is pulling back in Thursday's session after a strong run, trading near $411 and underperforming the broader market. The stock climbed from September lows near $375 as a string of positive readouts rebuilt investor confidence, and some investors now question whether the …
AstraZeneca (NYSE:AZN) is slipping in Thursday's session even after agreeing to invest $2 billion in Summit Therapeutics (NASDAQ:SMMT) through preferred stock that converts into roughly 12% of the smaller company. The shares are trading near $158, down 2.06%, as rising Treasury yields, elevated oil …
Bio-Rad Laboratories (NYSE:BIO) is under pressure in a weak session for healthcare stocks, giving back ground after a run that left it near its 52-week high. The Hercules, California-based company makes life science research tools and clinical diagnostics products, and its shares are down …
Braveheart Bio (NASDAQ:BRVE) is climbing in Thursday's session after an investor forum laid out the case for BHB-1893, its lead candidate for hypertrophic cardiomyopathy, or HCM. The San Francisco-based clinical-stage company went public in August and focuses on novel therapies for HCM and other …
Please wait processing your request...